These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29269661)

  • 1. Pazopanib-induced Endothelial Injury with Podocyte Changes.
    Maruyama K; Nakagawa N; Suzuki A; Kabara M; Matsuki M; Shindo M; Ogawa Y; Hasebe N
    Intern Med; 2018 Apr; 57(7):987-991. PubMed ID: 29269661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
    Jeon SY; Lee NR; Yim CY
    BMC Nephrol; 2019 Jan; 20(1):1. PubMed ID: 30606155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
    Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
    J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
    Miaris N; Maltezou M; Papaxoinis G; Visvikis A; Samantas E
    Clin Genitourin Cancer; 2017 Feb; 15(1):e99-e103. PubMed ID: 27601362
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effective treatment of metastatic rhabdomyosarcoma with pazopanib].
    Hashimoto A; Takada K; Takimoto R; Horiguchi H; Sato T; Iyama S; Murase K; Ono K; Tatekoshi A; Hayashi T; Miyanishi K; Sato Y; Kobune M; Hirayama Y; Kitamura H; Nakanishi K; Masumori N; Hasegawa T; Kato J
    Gan To Kagaku Ryoho; 2014 Aug; 41(8):1041-4. PubMed ID: 25132042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
    Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
    Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intimal Sarcoma of the Pulmonary Artery Treated with Pazopanib.
    Funatsu Y; Hirayama M; Shiraishi J; Asakura T; Wakaki M; Yamada E; Fujimoto K; Satomi R; Inaki S; Murata Y; Oyamada Y
    Intern Med; 2016; 55(16):2197-202. PubMed ID: 27522994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
    Sorich MJ; Rowland A; Kichenadasse G; Woodman RJ; Mangoni AA
    Br J Cancer; 2016 Jun; 114(12):1313-7. PubMed ID: 27228299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
    du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
    J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report.
    De Sanctis R; Lorenzi E; Agostinetto E; D'Amico T; Simonelli M; Santoro A
    Medicine (Baltimore); 2019 Dec; 98(50):e18089. PubMed ID: 31852067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib induced pigmented lesions of the scrotum and the face in a patient with metastatic renal cancer.
    Kostaki M; Stathopoulou A; Plaka M; Zaras A; Chatzidimitriou E; Dimitrakopoulou A; Christofidou E; Polydorou D; Stratigos A
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):e361-e362. PubMed ID: 31066082
    [No Abstract]   [Full Text] [Related]  

  • 12. Interstitial Lung Disease Induced by Pazopanib Treatment.
    Ide S; Sakamoto N; Hara S; Hara A; Kakugawa T; Nakamura Y; Futsuki Y; Izumikawa K; Ishimatsu Y; Yanagihara K; Mukae H
    Intern Med; 2017; 56(1):79-83. PubMed ID: 28050004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qi-Dan Fang ameliorates adriamycin-induced nephrotic syndrome rat model by enhancing renal function and inhibiting podocyte injury.
    Wu JB; Ye SF; Liang CL; Li YC; Yu YJ; Lai JM; Lin H; Zheng J; Zhou JY
    J Ethnopharmacol; 2014 Feb; 151(3):1124-1132. PubMed ID: 24389029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
    Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib: therapeutic developments.
    Limvorasak S; Posadas EM
    Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
    Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
    Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
    Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
    Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation recall dermatitis induced by pazopanib.
    Azad A; Maddison C; Stewart J
    Onkologie; 2013; 36(11):674-6. PubMed ID: 24192773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
    Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
    Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of abscesses during treatment with pazopanib in metastatic renal cancer: a case report.
    Puliafito I; Russo A; Sciacca D; Puglisi C; Giuffrida D
    J Med Case Rep; 2020 Jan; 14(1):7. PubMed ID: 31924259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.